1.0 Introduction

By 3–4 months of age (when fetal hemoglobin declines to <50% of total), many children with sickle cell anemia (HbSS) and sickle β-thalassemia develop clinically significant hemolytic anemia and impairment of splenic function. In others, although the HbF may remain above 50% these children are still at risk of splenic hypo function. Even though the spleen may be enlarged during the first years of life, its phagocytic function is markedly reduced. Therefore, children with sickle cell anemia are at risk of overwhelming septicemia, often without a primary focus, due to encapsulated organisms, including Streptococcus pneumonia and Haemophilus influenza type B.

This clinical practice guideline has been developed for the management of febrile patients with sickle cell disease who present to the emergency department or are inpatients.

2.0 Preventative Management

- To reduce high mortality, we strongly recommend:
  - Early diagnosis of sickle cell anemia by newborn screening and referral to a comprehensive care program for sickle cell disease. With newborn screening in place since November 2006, patients should be seen within 3 months of birth.
  - Prophylactic penicillin or amoxicillin, to be prescribed as soon as sickle cell disease is diagnosed, and continued until at least 5 years of age (to be continued past the age of 5 years in certain circumstances). In patients with significant beta-lactam allergy, trimethoprimsulfamethoxazole should be used.
  - Vaccination against pneumococcus, meningococcus and haemophilus influenza type B. Annual influenza vaccine is also recommended.

- Despite these measures, septicemia may still occur. Whenever a child with sickle cell disease has an oral or rectal temperature >38.5°C or an axillary temperature >38°C, he or she should be seen urgently. Febrile young infants (<3 months of age) should have an appropriate infectious work up, irrespective of their sickle cell status.
3.0 Clinical Recommendations for Management of Fever in Patients with Sickle Cell Disease

Emergency Department Initial Assessment and Management:
1. Complete history, physical exam, and routine investigations as per Sickle Cell Disease guidelines.
2. Evaluate for risk factors for sepsis and meningitis.
3. Consider blood culture and additional investigations as per Sickle Cell Disease guidelines.
4. Refer to hematology service for all patients with the following: fever without focus, patients with clinical symptoms of urinary tract infection (UTI) i.e. dysuria, frequency or dysuria and all children with history of urinary tract infection (UTI).
5. Consult hematology service for all patients with acute chest syndrome (ACS).

Emergency Department Monitoring:
- Vital signs:
  - Blood pressure
  - Pulse
  - Oxygen saturation
  - Temperature
- Lab investigations:
  - CBC, differential, reticulocyte count
  - Sodium, potassium
  - Platelet count
  - Complete history
  - Baseline hemoglobin

Inpatient Care:
- Antibiotics within 60 minutes of presentation for all patients with fever.
- Stable patients may be transferred to the Satellite SCD unit for further management.
- Refer to inpatient management document.
- Inpatient care should be guided by the following:
  - Baseline hemoglobin
  - Platelet count
  - CBC, differential
  - Sodium, potassium

4.0 References


©The Hospital for Sick Children ("SickKids"). All Rights Reserved. This document was developed solely for use at SickKids. SickKids accepts no responsibility for use of this material by any person or organization not associated with SickKids. A printed copy of this document may not reflect the current, electronic version on the SickKids intranet. Use of this document in any setting must be subject to the professional judgment of the user. No part of the document should be used for publication without prior written consent of SickKids.


### 5.0 Related documents

- [Acute Painful Episodes Vaso-occlusive Crisis: Guidelines for Management in Children with Sickle Cell Disease](#)
- [Acute Chest Syndrome or Pneumonia: Guidelines for Management in Children with Sickle Cell Disease](#)

### Attachments:

- [Fever Care Pathway Final 2021.pdf](#)
- [Revision History.docx](#)
- [SC_Clinic Follow Up Revised 2021_FINAL.pdf](#)
- [SCD fever_criteria for admission 2021 FINAL.pdf](#)
- [SCD fever_discharge planning process 2021 FINAL.pdf](#)
- [SCD fever_inpatient management.pdf](#)
- [SCD fever_out patient follow up.pdf](#)
- [SCD pain plan_july 2015.pdf](#)